Tissue Regenix Group (LSE:TRX) EV-to-EBITDA : 134.53 (As of May. 22, 2024)

Tissue Regenix Group EV-to-EBITDA Chart

Tissue Regenix Group Annual Data
	Trend	Jan14	Jan15	Jan16	Dec17	Dec18	Dec19	Dec20	Dec21	Dec22	Dec23
EV-to-EBITDA		Get a 7-Day Free Trial					-1.79	-3.86	-14.68	-53.78	113.12

Tissue Regenix Group Semi-Annual Data
	Jan14	Jul14	Jan15	Jul15	Jan16	Jul16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
EV-to-EBITDA	Get a 7-Day Free Trial															-14.68	-	-53.78	-	113.12

Competitive Comparison of Tissue Regenix Group's EV-to-EBITDA

For the Biotechnology subindustry, Tissue Regenix Group's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Tissue Regenix Group's EV-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Tissue Regenix Group's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Tissue Regenix Group's EV-to-EBITDA falls into.

Tissue Regenix Group EV-to-EBITDA Calculation

Tissue Regenix Group's EV-to-EBITDA for today is calculated as:

Tissue Regenix Group's current Enterprise Value is £47.49 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Tissue Regenix Group's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was £0.35 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Tissue Regenix Group  (LSE:TRX) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Tissue Regenix Group's PE Ratio for today is calculated as:

Tissue Regenix Group's share price for today is £0.62.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Tissue Regenix Group's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was £-0.019.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.

Please read Which price ratio outperforms the enterprise multiple?

Tissue Regenix Group EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Tissue Regenix Group's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.

Tissue Regenix Group (LSE:TRX) Business Description